KAKatherine Hermida Alava

Katherine Hermida Alava

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katherine Hermida Alava has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Voriconazole-Loaded Nanohydrogels Towards Optimized Antifungal Therapy for Cystic Fibrosis Patients

    by Shaul D. Cemal, María F. Ladetto, Katherine Hermida Alava, Gila Kazimirsky, Marcela Cucher, Romina J. Glisoni, María L. Cuestas, Gerardo Byk

    Background/Objectives: Filamentous fungi, in particular the species Aspergillus, Scedosporium, and Exophiala, frequently colonize the lungs of cystic fibrosis (CF) patients. Chronic colonization is linked to hypersensitivity reactions and persistent infections leading to a significant long-term decline in lung function. Azole antifungal therapy such as voriconazole (VRC) slows disease progression, particularly in patients with advanced CF; however, excessive mucus production in CF lungs poses a diffusional barrier to effective treatment. Methods: Here, biodegradable nanohydrogels (NHGs) recently developed as nanocarriers were evaluated for formulating VRC as a platform for treating fungal infections in CF lungs. The NHGs entrapped up to about 30 μg/mg of VRC, and physicochemical properties were investigated via dynamic laser light scattering and nanoparticle tracking analysis. Diameters were 100–400 nm, and excellent colloidal stability was demonstrated in interstitial fluids, indicating potential for pulmonary delivery. Nano-formulations exhibited high in vitro cytocompatibility in A549 and HEK293T cells and were tested for the release of VRC under two different sink conditions. Results: Notably, the antifungal activity of VRC-loaded nanohydrogels was up to eight-fold greater than an aqueous suspension drug against different fungal species isolated from CF sputum, regardless of the presence of a CF artificial mucus layer. Conclusions: These findings support the development of potent VRC nano-formulations for treating fungal disorders in CF lungs.


  • Open Access

    Voriconazole-Loaded Nanohydrogels Towards an Optimized Antifungal Therapy for Cystic Fibrosis Patients

    by Shaul Deniz Cemal, Maria Florencia Ladetto, Katherine Hermida Alava, Gila Kazimirsky, Marcela Alejandra Cucher, Romina Glisoni, María Lujan Cuestas, Gerardo Byk

    Filamentous fungi, in particular the species Aspergillus, Scedosporium and Exophiala, frequently colonize the lungs of cystic fibrosis (CF) patients. Chronic colonization is linked to hypersensitivity reactions and persistent infections leading to a significant long-term decline in lung function. Azole antifungal therapy such as voriconazole (VRC) slows disease progression, in particular in patients with advanced CF; however, excessive mucus production in CF lungs poses a diffusional barrier to effective treatment. Here, biodegradable nanohydrogels (NHGs) recently developed as nanocarriers, were evaluated for formulating VRC as a platform for treating fungal infections in CF lungs. The NHGs entrapped up to about 30 μg/mg of VRC, and physicochemical properties were investigated by dynamic laser light scattering and nanoparticle tracking analysis. Diameters were 100–400 nm, and excellent colloidal stability was demonstrated in interstitial fluids indicating potential for pulmonary delivery. Nano-formulations exhibited high in vitro cytocompatibility in A549 and HEK293T cells and were tested for release of VRC under two different sink conditions. Notably, the antifungal activity of VRC-loaded nanohydrogels was at least two-fold greater than an aqueous suspension drug against different fungal species isolated from CF sputum, regardless of the presence of a CF artificial mucus layer. These findings support the development of potent VRC nano-formulations for treating fungal disorders in CF lungs.


  • Highly effective inhalable voriconazole-loaded nanomicelles for fungal infections in cystic fibrosis patients: A promising therapeutic strategy for allergic bronchopulmonary aspergillosis

    by Víctor Briceño Fernández, Katherine Hermida Alava, Ezequiel Bernabeu, Pedro Fuentes, Tomas Brito Devoto, Christian Höcht, Diego A. Chiappetta, María L. Cuestas, Marcela A. Moretton


  • Exploring fungal diversity in Antarctic wildlife: isolation and molecular identification of culturable fungi from penguins and pinnipeds

    by T Brito Devoto, Ma Toscanini, K Hermida Alava, An Etchecopaz, Sj Pola, Mm Martorell, M Ansaldo, J Negrete, L Ruberto, W Mac Cormack, et al.

    To survey the diversity of fungal species that may be cultured from Antarctic penguins and pinnipeds, and to test the in vitro susceptibility to triazole drugs of any medically important Aspergillu...


  • Molecular epidemiology of Aspergillus species and other moulds in respiratory samples from Argentinean patients with cystic fibrosis

    by Tomás Brito Devoto, Katherine Stefania Hermida Alava, Santiago J Pola, Rosana Pereda, Etelvina Rubeglio, Jorge L Finquelievich, María L Cuestas

    In cystic fibrosis (CF) patients, fungal colonization of the respiratory tract is frequently found. Aspergillus fumigatus is the most frequently recorded and is associated with loss of pulmonary function and allergic disease (ABPA). The knowledge on prevalence rates of filamentous fungi in CF patients in Latin America is scarce. One hundred and seventy-six fungal isolates recovered from the upper respiratory tract of CF patients from Argentina were identified to species by morphology and DNA sequencing. In total, 90% of CF patients were colonized by Aspergillus sp., followed by Exophiala sp. (14%) and Scedosporium sp. (10%). Among Aspergillus, six species complexes (Fumigati, Flavi, Terrei, Nigri, Usti, and Nidulante) and different cryptospecies were found. Among Scedosporium, three species were observed (Scedosporium apiospermum, Scedosporium aurantiacum and Scedosporium boydii). All Exophiala isolates were identified as Exophiala dermatitidis. Rare filamentous fungi were also found. All cases of ABPA were associated to the presence of A. fumigatus. Mixed colonization with other mould or rare fungi was observed in half of them. To our knowledge, this is the first prospective study of mould species in CF using molecular methods in Latin America. This study shows that Aspergillus sp., E. dermatitidis and Scedosporium sp. have a high frequency in CF patients from Argentina, and by far, A. fumigatus was the most commonly cultured species. Continuous clinical surveillance is required to detect the emergence of new fungal pathogens and to detect resistant or difficult-to-treat species capable of chronic colonizing the airways and of hematogenous dissemination in case of lung transplantation.


  • Open Access

    Análisis genético de las mutaciones presentes en las poblaciones virales en pacientes con infección por VIH-1 en Ecuador

    by Manuel González-González, Consuelo Correa-Sierra, Katherine Hermida-Álava, Ana Machado-Díaz, L. Fernando Gómez-Andrade, Martha Castillo-Segovia, C. Lissette Pérez-Santos, Vivian Kourí-Cardellá

    Palabras clave Ecuador; VIH; resistencia; anti-retroviral; mutaciones; subtipos